The sequence of application of methotrexate and histone deacetylase inhibitors determines either a synergistic or an antagonistic response in childhood acute lymphoblastic leukemia cells

Leukemia

Volumn 25, Issue 2, 2011, Pages 359-361

  Bastian, L ^a   Einsiedel, H G ^a   Henze, G ^a   Seeger, K ^a   Shalapour, S ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; VALPROIC ACID; VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; APOPTOSIS; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CHILDHOOD CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LETTER; LEUKEMIA CELL; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL;

EID: 79751528411     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.259     Document Type: Letter

References (8)

1. Leclerc GJ, Mou C, Leclerc GM, Mian AM, Barredo JC. Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy. Leukemia 2010; 24: 552-562.
2. Einsiedel HG, Kawan L, Eckert C, Witt O, Fichtner I, Henze G et al. Histone deacetylase inhibitors have antitumor activity in two NOD/ SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia. Leukemia 2006; 20: 1435-1436. (Pubitemid 44084058)
3. Webb JL. Effect of More than One Inhibitor. Enzymes and Metabolic Inhibitors, vol. 1. Academic Press: New York, 1963, pp 66-79 and 487-512.
4. Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Mano H et al. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/ lymphoma cell lines. Invest New Drugs 2007; 25: 31-40. (Pubitemid 44657640)
5. Prasad P, Vasquez H, Das CM, Gopalakrishnan V, Wolff JE. Histone acetylation resulting in resistance to methotrexate in choroid plexus cells. J Neurooncol 2009; 91: 279-286.
6. Sur P, Fernandes DJ, Kute TE, Capizzi RL. L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y. Cancer Res 1987; 47: 1313-1318. (Pubitemid 17023201)
7. Fernandes DJ, Sur P, Kute TE, Capizzi RL. Proliferation-dependent cytotoxicity of methotrexate in murine L5178Y leukemia. Cancer Res 1988; 48: 5638-5644.
8. Wolfrom C, Hartmann R, Fengler R, Bruhmuller S, Ingwersen A, Henze G. Randomized comparison of 36-h intermediate-dose versus 4-h high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol 1993; 11: 827-833. (Pubitemid 23146075)